Angion Biomedica (ANGN) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Angion Biomedica in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ANGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANGN, but not buy additional shares or sell existing shares.
View ANGN analyst ratings or view top-rated stocks.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ANGN earnings forecast.

Angion Biomedica Corp. (NASDAQ:ANGN) announced its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The business had revenue of $1.46 million for the quarter, compared to analyst estimates of $1.08 million.

Shares of Angion Biomedica reverse split before market open on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

(ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

Angion Biomedica trades on the NASDAQ under the ticker symbol "ANGN."

Angion Biomedica's stock is owned by many different retail and institutional investors. Top institutional investors include CM Management LLC (2.66%) and Renaissance Technologies LLC (0.31%). Insiders that own company stock include Allen Nissenson, Itzhak Goldberg, Jay Venkatesan, Jennifer J Rhodes, Jennifer J Rhodes, John F Neylan and Victor F Ganzi.
View institutional ownership trends.

Shares of ANGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Angion Biomedica (NASDAQ:ANGN) has a market capitalization of $0.00 and generates $2.30 million in revenue each year.

Angion Biomedica's mailing address is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. The official website for the company is www.angion.com. The company can be reached via phone at 415-655-4899 or via email at daniel@lifesciadvisors.com.